California-based pharmaceutical company Seragon Biosciences Inc announced on Tuesday the launch of Enlivien, a sleep and longevity optimiser.

The company says that Enlivien integrates a proprietary combination of anti-oxidative and anti-inflammatory compounds alongside mitochondrial-supporting molecules. It is designed to preserve redox homeostasis, the internal chemistry that controls reactive oxygen radicals (ROS), and support mitochondrial function. These systems are especially vulnerable during periods of sleep disruption, when ROS accumulates and overwhelms the body. Enlivien is also designed to target the cascade of biological disruptions linked to impaired nutrient absorption, compromised intestinal barrier integrity, and increased mortality risk observed in preclinical studies.

Enlivien targets the underlying molecular pathways disrupted by insufficient sleep. Its proprietary formulation combines anti-oxidative and anti-inflammatory compounds with mitochondrial-supporting molecules, delivered through Seragon's advanced ingredient delivery technologies to help maximise bioavailability and effectiveness.